Nat Commun:IL-17A可用于肺癌治疗
2012-01-06 MedSci原创 MedSci原创
近日,国际著名杂志Nature Communications刊登了德国埃朗根-纽伦堡大学医院研究人员的最新研究成果“A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer”,文章中指出,该院研究人员开发出一种治疗肺癌的新方法,通过引入抗体阻断一种促进肿瘤生长的“信使物质
近日,国际著名杂志Nature Communications刊登了德国埃朗根-纽伦堡大学医院研究人员的最新研究成果“A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer”,文章中指出,该院研究人员开发出一种治疗肺癌的新方法,通过引入抗体阻断一种促进肿瘤生长的“信使物质”,可提高肺癌患者的存活率。
据介绍,研究人员发现人体免疫系统中一种名为白介素-17A的“信使物质”会促进肿瘤生长,而这种物质往往会在肺癌患者体内大量出现。
摸清了免疫系统的“工作流程”后,研究人员开始探索治疗肺癌的新方法,结果发现,引入某种抗体“封锁”上述“信使物质”后,可有效抑制肿瘤增长,提高患者存活率。此外,研究人员没有采取传统的注射方法给患者引入抗体,而是通过滴鼻剂的方式引入。
据世界卫生组织的数据,肺癌不但是最常见的一种癌症,它导致的死亡人数也比其它癌症高。(生物谷Bioon.com)
A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer
S. Reppert,I. Boross,M. Koslowski,Ö. Türeci,S. Koch,H.A. Lehr&S. Finotto
Lung cancer is the leading cause of cancer deaths worldwide. The cytokine interleukin-17A supports tumour vascularization and growth, however, its role in lung cancer is unknown. Here we show, in the lungs of patients with lung adenocarcinoma, an increase in interleukin-17A that is inversely correlated with the expression of T-bet and correlated with the T regulatory cell transcription factor Foxp3. Local targeting of interleukin-17A in experimental lung adenocarcinoma results in a reduction in tumour load, local expansion of interferon-γ-producing CD4+ T cells and a reduction in lung CD4+CD25+Foxp3+ regulatory T cells. T-bet(−/−) mice have a significantly higher tumour load compared with wild-type mice. This is associated with the local upregulation of interleukin-23 and induction of interleukin-17A/interleukin-17R-expressing T cells infiltrating the tumour. Local anti-interleukin-17A antibody treatment partially improves the survival of T-bet(−/−) mice. These results suggest that local anti-interleukin-17A antibody therapy could be considered for the treatment of lung tumours.
版权声明:
本网站所有注明“来源:梅斯医学”或“来源:MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明“来源:梅斯医学”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
#COMMUN#
60
#Nat#
59
#肺癌治疗#
62
#IL-17#
59
#IL-17A#
72